Navigation Links
Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Date:4/24/2008

CRANBURY, N.J., April 24 /PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at the Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, April 30, 2008, at 2:20 p.m. EDT, at the Ritz-Carlton in Key Biscayne, Florida.

The presentation will be webcast live and may be accessed by visiting Amicus' website at http://www.amicustherapeutics.com. A replay of the webcast will also be available on the Company's website for 30 days until May 30, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. The Company recently completed Phase I clinical trials of AT2220 for the treatment of Pompe disease.

CONTACTS:

Investors: Media:

John Quirk Cory Tromblee

Porter Novelli Life Sciences Porter Novelli Life Sciences

(212) 601-8296 (617) 897-8294


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... , ... July 17, 2017 ... ... technology-enabled clinical trial solutions, today announced safety software company AB Cube has ... eHealth Solutions business segment to advance technology innovation across life sciences and ...
(Date:7/17/2017)... ... July 17, 2017 , ... ... Hsing, Ph.D. , recently participated in the BiG (Biomedical Innovation Group) annual meeting ... by discussions of CAR-T (chimeric antigen receptor T-cell) therapy, a rapidly developing highly ...
(Date:7/16/2017)... N.J. (PRWEB) , ... July 16, 2017 , ... ... laboratory equipment and analytical instruments announced the launch of its new line of ... introduced five rocking and waving shaker models (both analog and digital) for laboratory ...
(Date:7/14/2017)... ... July 14, 2017 , ... ... company . Sonic Manufacturing Technologies has installed a solar system on its roof ... three-year period,” the President of Sonic, Kenneth Raab stated. The company’s proud history ...
Breaking Biology Technology:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
Breaking Biology News(10 mins):